Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Alector Inc

ALEC ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: HOLD

Last Close

$1.96

▼ -3.92%

Market Cap $218.85M · Vol 189.50K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$218.85M

Micro Cap

Div Yield

N/A

EPS Growth

+36.69%

YoY

RSI (14)

65.73

Momentum

Beta

0.66

vs Market

52W High

$3.40

42.27% below

52W Low

$1.10

79.00% above

Volume

189.50K

Avg 245.86K

P/B

5.62

Price-to-book

ROE

-181.56%

Return on equity

Free Float

86.82%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Alector Inc (ALEC) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ALEC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+10.11%

+41.01%

-14.78%

+4.81%

YTD

+25.64%

-20.33%

-73.80%

-93.08%

Financials & Valuation

TTM · Annual

Total Revenue	$21.05M
Net Income	$-142,929,000.00
Revenue Growth (YoY)	-57.84%
Gross Margin	100.00%
Operating Margin	-741.30%
Net Profit Margin	-679.16%
ROE	-181.56%
ROA · ROIC	-37.49% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	7.63
P/B	5.62
P/FCF	N/A
EPS Growth	+36.69%
Outstanding Shares	111.66M

Technical Indicators

50-Day SMA	$1.69
200-Day SMA	$1.85
RSI (14)	65.73
Beta	0.66
52-Week High	$3.40
52-Week Low	$1.10

Volume Today	189.50K
Avg Daily Volume (30D)	245.86K
Relative Volume	0.77x
Volatility (10D)	150.56
Volatility (30D)	112.69
Free Float	86.82%

Analyst Consensus

HOLD

Current Price $1.96

Mean Target $3.10

52W Low$1.10 52W High$3.40

Current

Target

$1.10 $3.40

Current Analyst target

+58.16% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00N0PL214

ISINUS0144421072

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.